NexGard Spectra – 3 chewable tablets

NEXGARD SPECTRA – antiparasitic chewable tablets for dogs
Nexgard Spectra is indicated for the treatment of flea and tick infestations in dogs when the prevention of heartworm, angiostrongylosis, thelaziosis and/or the treatment of gastrointestinal worm infestations is also indicated. Being extremely useful in the treatment of flea and tick infestations.

In the treatment of adult gastrointestinal nematode infestations of the following species: roundworms, hookworms and whipworms.

Nexgard Spectra can be used in: the treatment of canine demodicosis, the treatment of sarcoptic mange, in the prevention of heartworm, in the prevention of angiostrongylosis, in the prevention of thelaziosis.

INDICATIONS:

For the treatment of flea and tick infestations in dogs when the prevention of heartworm disease (Dirofilaria immitis larval stage), angiostrongylosis (reduction of the level of Angiostrongylus vasorum infestation in the immature adult (L5) and adult stages), thelazia (Thelazia callipaeda adult) and/or the treatment of gastrointestinal worm infestations is also indicated.
Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs.
Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus) in dogs.
Fleas and ticks must be attached to the host and begin feeding to be exposed to the active substance.
Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxocara leonina), hookworms (Ancyclostoma caninum, Ancyclostoma braziliense and Ancyclostoma ceylanicum) and whipworms (Trichuris vulpis)
Treatment of canine demodicosis (caused by Demodex canis).
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).
Prevention of heartworm disease (Dirofilaria immitis larval stage) when administered monthly.
Prevention of angiostrongylosis (by reducing the level of infestation with Angiostrongylus vasorum in the immature adult (L5) and adult stages) when administered monthly.
Prevention of thelaziasis (eye infection with Thelazia callipaeda adult form) when administered monthly.
CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

ADVERSE REACTIONS

Clinical studies

Vomiting, diarrhoea, lack of energy, decreased appetite and itching have been observed less frequently. These reactions have generally resolved spontaneously and were of short duration.

Post-marketing safety experience

Erythema and neurological signs (convulsions, ataxia and muscle tremor) have been reported very rarely.

The frequency of adverse reactions is defined using the following convention:

– Very common (more than 1 in 10 animals treated displaying adverse reactions)

– Common (more than 1 but less than 10 animals in 100 animals treated)

– Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

– Rare (more than 1 but less than 10 animals in 10,000 animals treated)

– Very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

If you notice any adverse reactions, even those not already listed in this leaflet, or you think that the medicinal product has had no effect, please inform your veterinary surgeon.

METHOD OF ADMINISTRATION

For oral use.
Dosage:

The product should be administered according to the following table:

For dogs over 60 kg body weight, the required combination of chewable tablets should be used

Method of administration:

The tablets are chewable and palatable to most dogs. If the dog does not accept the tablets directly, they can be administered with food.